![]() | |
![]() | |
Names | |
---|---|
Preferred IUPAC name
4-(8-Methyl-2H,9H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)aniline | |
Identifiers | |
| |
3D model (
JSmol)
|
|
ChEBI | |
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.162.378 |
KEGG | |
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C17H15N3O2 | |
Molar mass | 293.326 g·mol−1 |
Appearance | Yellow solid (HCl salt) |
Density | 1.393 g/cm3 |
>10 mg/mL (HCl salt) | |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
GYKI 52466 is a 2,3- benzodiazepine that acts as an ionotropic glutamate receptor antagonist, which is a non-competitive AMPA receptor antagonist (IC50 values are 10-20, ~ 450 and >> 50 μM for AMPA-, kainate- and NMDA-induced responses respectively), orally-active anticonvulsant, and skeletal muscle relaxant. [1] [2] [3] [4] Unlike conventional 1,4-benzodiazepines, GYKI 52466 and related 2,3-benzodiazepines do not act on GABAA receptors. [5] Like other AMPA receptor antagonists, GYKI 52466 has anticonvulsant and neuroprotective properties. [6]
![]() | |
![]() | |
Names | |
---|---|
Preferred IUPAC name
4-(8-Methyl-2H,9H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)aniline | |
Identifiers | |
| |
3D model (
JSmol)
|
|
ChEBI | |
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.162.378 |
KEGG | |
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C17H15N3O2 | |
Molar mass | 293.326 g·mol−1 |
Appearance | Yellow solid (HCl salt) |
Density | 1.393 g/cm3 |
>10 mg/mL (HCl salt) | |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
GYKI 52466 is a 2,3- benzodiazepine that acts as an ionotropic glutamate receptor antagonist, which is a non-competitive AMPA receptor antagonist (IC50 values are 10-20, ~ 450 and >> 50 μM for AMPA-, kainate- and NMDA-induced responses respectively), orally-active anticonvulsant, and skeletal muscle relaxant. [1] [2] [3] [4] Unlike conventional 1,4-benzodiazepines, GYKI 52466 and related 2,3-benzodiazepines do not act on GABAA receptors. [5] Like other AMPA receptor antagonists, GYKI 52466 has anticonvulsant and neuroprotective properties. [6]